Soluble ENPP1 proteins and uses thereof
AssigneesBiomarin Pharmaceutical Inc., Yale University
InventorsZhiliang Cheng, Demetrios Braddock, Paul Stabach, Steven Jungles
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present invention provides novel soluble ENPP1 or ENPP3 polypeptides, as well as compositions and methods for using those variants to treat an indication associated an ENPP1 or ENPP3 deficiency. The compositions and methods provided herein are useful in treating diseases associated with an ENPP1 or ENPP3 deficiency such as pathological calcification or pathological ossification.
Claims6
A soluble ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) polypeptide that lacks both Somatomedin B (SMB) domain 1 and SMB domain 2 of ENPP1, and wherein the soluble ENPP1 polypeptide is at least 90% identical to the amino acid sequence of SEQ ID NO:
- 121 and the catalytic domain of the ENPP1 portion of the soluble ENPP1 polypeptide comprises a 1332T substitution and the Fc domain comprises a triple mutation (M252Y, S254T, T256E).
Dependencies are inferred from the claim text.